Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421664 · ClinicalTrials.gov registry record · Phase 3
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
A Phase 3 study, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.
- Terminated
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
NCT04421664: Clinical Trial Phase 3 study, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.
NCT04421664 is a Phase 3 study that was terminated before completion, run by McGill University Health Centre/Research Institute of the McGill University Health Centre. The registered enrollment target is 70 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04421664, a Phase 3 study, was terminated before completion, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
Study Summary
Study Objective: To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.
Primary Outcome
Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the percent of participants who fall into each category per arm.
Interventions
- DRUG Placebo oral tablet
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-03-25 |
| Est. Completion | 2020-08-17 |
| Phase | Phase 3 |
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre9 total trials
Why NCT04421664 stopped before completion
NCT04421664 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04421664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04421664 about?
NCT04421664 is a clinical study titled "Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)". Study Objective: To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.
What is the current status of trial NCT04421664?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2020-03-25. Estimated completion is 2020-08-17.
What interventions are being tested in trial NCT04421664?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04421664?
This trial is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04421664's enrollment target sits among peer trials
70 1785th of 2000 higher than 208 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI